270 related articles for article (PubMed ID: 29230121)
1. Leptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy.
Thomas KH; Ramirez RA
Ochsner J; 2017; 17(4):362-378. PubMed ID: 29230121
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
3. Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.
Piña Y; Yadugiri S; Yeboa DN; Ferguson SD; Forsyth PA; Oliva ICG
Curr Oncol Rep; 2022 Jan; 24(1):43-54. PubMed ID: 35059999
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy for leptomeningeal disease in breast cancer.
Bartsch R; Jerzak KJ; Larrouquere L; Müller V; Le Rhun E
Cancer Treat Rev; 2024 Jan; 122():102653. PubMed ID: 38118373
[TBL] [Abstract][Full Text] [Related]
5. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Chorti E; Kebir S; Ahmed MS; Keyvani K; Umutlu L; Kanaki T; Zaremba A; Reinboldt-Jockenhoefer F; Knispel S; Gratsias E; Roesch A; Ugurel S; Scheffler B; Schadendorf D; Livingstone E; Meier F; Glas M; Zimmer L
Eur J Cancer; 2021 May; 148():395-404. PubMed ID: 33789203
[TBL] [Abstract][Full Text] [Related]
6. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).
Ferguson SD; Bindal S; Bassett RL; Haydu LE; McCutcheon IE; Heimberger AB; Li J; O'Brien BJ; Guha-Thakurta N; Tetzlaff MT; Tawbi H; Davies MA; Glitza IC
J Neurooncol; 2019 May; 142(3):499-509. PubMed ID: 30847840
[TBL] [Abstract][Full Text] [Related]
7. Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease.
Mills MN; King W; Soyano A; Pina Y; Czerniecki BJ; Forsyth PA; Soliman H; Han HS; Ahmed KA
J Neurooncol; 2022 Apr; 157(2):249-269. PubMed ID: 35244835
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and Therapeutic Updates in Leptomeningeal Disease.
Roy-O'Reilly MA; Lanman T; Ruiz A; Rogawski D; Stocksdale B; Nagpal S
Curr Oncol Rep; 2023 Aug; 25(8):937-950. PubMed ID: 37256537
[TBL] [Abstract][Full Text] [Related]
9. Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases.
Khaled ML; Tarhini AA; Forsyth PA; Smalley I; Piña Y
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980770
[TBL] [Abstract][Full Text] [Related]
10. Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.
Kingston B; Kayhanian H; Brooks C; Cox N; Chaabouni N; Redana S; Kalaitzaki E; Smith I; O'Brien M; Johnston S; Parton M; Noble J; Stanway S; Ring A; Turner N; Okines A
Breast; 2017 Dec; 36():54-59. PubMed ID: 28968585
[TBL] [Abstract][Full Text] [Related]
11. Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment.
Steininger J; Gellrich FF; Engellandt K; Meinhardt M; Westphal D; Beissert S; Meier F; Glitza Oliva IC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511202
[TBL] [Abstract][Full Text] [Related]
12. Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape.
Nguyen A; Nguyen A; Dada OT; Desai PD; Ricci JC; Godbole NB; Pierre K; Lucke-Wold B
Curr Oncol; 2023 Jun; 30(6):5906-5931. PubMed ID: 37366925
[TBL] [Abstract][Full Text] [Related]
13. Leptomeningeal disease in glioblastoma: endgame or opportunity?
Akmal S; Ginalis EE; Patel NV; Aiken R; Dicpinigaitis AJ; Hanft SJ
J Neurooncol; 2021 Nov; 155(2):107-115. PubMed ID: 34623599
[TBL] [Abstract][Full Text] [Related]
14. Latest clinical research in leptomeningeal disease (LMD)-a narrative review.
Chan AW; Wong HCY; Taphoorn M; Dirven L; Le Rhun E; Soliman H; Oldenburger E; Raman S; Vassiliou V; Bonomo P; Koller M; Marta GN; Rembielak A; Lee SF; Chow E; Simone CB
Ann Palliat Med; 2023 Nov; 12(6):1215-1231. PubMed ID: 37953219
[TBL] [Abstract][Full Text] [Related]
15. Breast leptomeningeal disease: a review of current practices and updates on management.
Figura NB; Rizk VT; Armaghani AJ; Arrington JA; Etame AB; Han HS; Czerniecki BJ; Forsyth PA; Ahmed KA
Breast Cancer Res Treat; 2019 Sep; 177(2):277-294. PubMed ID: 31209686
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy in Leptomeningeal Disease: A Systematic Review of Randomized and Non-randomized Trials.
Buszek SM; Chung C
Front Oncol; 2019; 9():1224. PubMed ID: 31803614
[No Abstract] [Full Text] [Related]
17. Factors improving overall survival in breast cancer patients with leptomeningeal disease (LMD): A single institutional retrospective review.
Wallace G; Kundalia R; Cao B; Kim Y; Smalley I; Forsyth P; Soyano A; Pina Y
Res Sq; 2023 Jun; ():. PubMed ID: 37333166
[TBL] [Abstract][Full Text] [Related]
18. Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease.
Dan X; Huang M; Sun Z; Chu X; Shi X; Chen Y
Front Oncol; 2024; 14():1344829. PubMed ID: 38665955
[TBL] [Abstract][Full Text] [Related]
19. Durable complete remission of leptomeningeal melanoma by intrathecal methotrexate maintained with systemic ipilimumab.
Dietrich C; Salzmann M; Steinbrecher A; Herbst R; Hassel JC
Immunotherapy; 2021 Sep; 13(13):1079-1083. PubMed ID: 34259028
[TBL] [Abstract][Full Text] [Related]
20. Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD).
Ferguson SD; Fomchenko EI; Guerrieri RA; Glitza Oliva IC
Front Oncol; 2021; 11():800053. PubMed ID: 35096602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
